All pages
Jump to navigation
Jump to search
- ADAMTS13, recombinant (Adzynma)
- ASCO guidelines
- Abarelix (Plenaxis)
- Abciximab (ReoPro)
- Abemaciclib (Verzenio)
- Abexinostat (PCI-24781)
- Abiraterone (Zytiga)
- Academic Medicine exhibit
- Academic Medicine standard narrative
- Academic Medicine wiki-based narrative
- Acalabrutinib (Calquence)
- Acetaminophen (Tylenol)
- Acetazolamide (Diamox)
- Aclarubicin (Aclacinon)
- Acquired hemophilia A
- Acquired thrombotic thrombocytopenic purpura
- Actinium Ac 225 lintuzumab (Actimab-A)
- Acute lymphoblastic leukemia, infant
- Acute lymphoblastic leukemia, infant - historical
- Acute myeloid leukemia
- Acute myeloid leukemia, FLT3-positive
- Acute myeloid leukemia, FLT3-positive - null regimens
- Acute myeloid leukemia, IDH-mutated
- Acute myeloid leukemia, NPM1-mutated
- Acute myeloid leukemia, pediatric
- Acute myeloid leukemia, pediatric - historical
- Acute myeloid leukemia - historical
- Acute myeloid leukemia - null regimens
- Acute myeloid leukemia trial demographics
- Acute promyelocytic leukemia
- Acute promyelocytic leukemia - null regimens
- Acyclovir (Zovirax)
- Adagrasib (Krazati)
- Adavosertib (MK-1775)
- Adebrelimab (SHR-1316)
- Adrenocortical carcinoma
- Adrenocortical carcinoma - null regimens
- Adult T-cell leukemia-lymphoma
- Adult T-cell leukemia-lymphoma - historical
- Afamitresgene Autoleucel (ADP-A2M4)
- Afatinib (Gilotrif)
- Afuresertib (GSK-2110183)
- Agatolimod (PF-3512676)
- Aggressive Non-Hodgkin lymphoma
- Aldesleukin (Proleukin)
- Alectinib (Alecensa)
- Alemtuzumab (Campath)
- Alendronate (Fosamax)
- Alisertib (MLN-8237)
- Alitretinoin (Panretin)
- Alizapride (Litican)
- All-trans retinoic acid (ATRA)
- Allogeneic HSCT
- Allogeneic stem cells
- Allopurinol (Zyloprim)
- Alpelisib (Piqray)
- Alprazolam (Xanax)
- Altretamine (Hexalen)
- Alveolar soft part sarcoma
- Alvocidib (Flavopiridol)
- Amatuximab (MORAb-009)
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Aminopterin
- Amivantamab (Rybrevant)
- Amonafide (Quinamed)
- Amoxicillin
- Ampicillin
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anakinra (Kineret)
- Anal cancer
- Anaplastic glioma
- Anaplastic glioma - null regimens
- Anaplastic large cell lymphoma
- Anaplastic large cell lymphoma, pediatric
- Anastrozole (Arimidex)
- Ancestim (Stemgen)
- Andexanet alfa (Andexxa)
- Anemia
- Angiosarcoma
- Anlotinib (Fukewei)
- Anti-inhibitor coagulant complex (FEIBA NF)
- Antidepressants and other psychiatric medications in cancer care
- Antiemesis
- Antimicrobial prophylaxis
- Antiphospholipid antibody syndrome
- Antithrombin III (human and recombinant)
- Antithymocyte globulin, horse ATG (Atgam)
- Antithymocyte globulin, rabbit ATG (Grafalon)
- Antithymocyte globulin, rabbit ATG (Thymoglobulin)
- Apalutamide (Erleada)
- Apatinib (Aitan)
- Apixaban (Eliquis)
- Aplastic anemia
- Appendiceal tumor
- Aprepitant (Emend)
- Argatroban (Acova)
- Aric's Test Page
- Aripiprazole (Abilify)
- Arsenic trioxide (Trisenox)
- Asciminib (Scemblix)
- Ascorbic acid (Vitamin C)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Asparaginase erwinia chrysanthemi-rywn (Rylaze)
- Aspirin
- Aspirin and dipyridamole (Aggrenox)
- Atenolol
- Atezolizumab (Tecentriq)
- Atovaquone (Mepron)
- Atropine (Atropen)
- Atypical hemolytic uremic syndrome
- Aumolertinib (Amelie)
- Autoimmune cytopenia
- Autologous HSCT
- Autologous stem cells
- Avapritinib (Ayvakit)
- Avatrombopag (Doptelet)
- Avelumab (Bavencio)
- Axicabtagene ciloleucel (Yescarta)
- Axitinib (Inlyta)
- Aymen's Test Page
- Azacitidine (Vidaza)
- Azacitidine oral (Onureg)
- Azathioprine (Imuran)
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia, Ph-positive
- B-cell acute lymphoblastic leukemia, pediatric
- B-cell acute lymphoblastic leukemia, pediatric, Ph-positive
- B-cell acute lymphoblastic leukemia, pediatric - historical
- B-cell acute lymphoblastic leukemia, pediatric - null regimens
- B-cell acute lymphoblastic leukemia - historical
- B-cell lymphoma of mucosa-associated lymphoid tissue
- B-cell lymphoma of mucosa-associated lymphoid tissue - historical
- B-cell lymphoma of mucosa-associated lymphoid tissue - null regimens
- BCG vaccine
- BE-CAR7
- BHQ-880
- BL22 immunotoxin (CAT-3888)
- Barasertib (AZD-1152)
- Basics of Pain Management
- Bavituximab (PGN-401)
- Belagenpumatucel-L (Lucanix)
- Belantamab mafodotin (Blenrep)
- Belinostat (Beleodaq)
- Belotecan (Camptobell)
- Belumosudil (Rezurock)
- Belzutifan (Welireg)
- Bendamustine
- Benralizumab (Fasenra)
- Beta thalassemia
- Beth Israel Deaconess Medical Center Hematology Oncology Fellowship
- Betrixaban (Bevyxxa)
- Bevacizumab-adcd (Vegzelga)
- Bevacizumab-awwb (Mvasi)
- Bevacizumab-aybi (Aybintio)
- Bevacizumab-bvzr (Zirabev)
- Bevacizumab-equi (Equidacent)
- Bevacizumab-maly (Alymsys)
- Bevacizumab-onbe (Onbevzi)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bilateral adrenalectomy
- Bilateral oophorectomy
- Bilateral orchiectomy
- Billing codes (CPT) and wRVUs
- Binimetinib (Mektovi)
- Biomarkers
- Birtamimab (NEOD-001)
- Bismuth subcitrate
- Bismuth subsalicylate (Pepto-Bismol)
- Bivalirudin (Angiomax)
- Bladder cancer
- Bladder cancer - historical
- Bladder cancer - null regimens
- Blastic plasmacytoid dendritic cell neoplasm
- Bleeding disorders and risk
- Bleeding with anticoagulation
- Bleomycin (Blenoxane)
- Blinatumomab (Blincyto)
- Bone marrow biopsy procedure instructions and information
- Bone sarcoma
- Borofalan-10B (Steboronine)
- Bortezomib (Velcade)
- Boston University Medical Center Hematology Oncology Fellowship
- Bosutinib (Bosulif)
- Brachytherapy
- Breast cancer
- Breast cancer, BRCA-mutated
- Breast cancer, CNS metastases
- Breast cancer, ER-positive
- Breast cancer, ER-positive - historical
- Breast cancer, ER-positive - null regimens
- Breast cancer, ER and HER2 co-expressing
- Breast cancer, HER2-positive
- Breast cancer, HER2-positive - historical
- Breast cancer, HER2-positive - null regimens
- Breast cancer, PIK3CA-mutated
- Breast cancer, triple negative
- Breast cancer, triple negative - null regimens
- Breast cancer - historical
- Breast cancer - null regimens
- Breast cancer BRCA1 & BRCA2 genetic testing
- Brentuximab vedotin (Adcetris)
- Brexucabtagene autoleucel (Tecartus)
- Brigatinib (Alunbrig)
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute Hematology Oncology Fellowship
- Bumetanide (Bumex)
- Buparlisib (BKM-120)
- Burkitt lymphoma
- Buserelin (Suprefact)
- Busulfan (Myleran)
- CART-EGFRvIII
- CAR T-cell toxicity management
- CARv3-TEAM-E T-cells
- CNS carcinoma
- CNS leukemia
- CNS lymphoma
- CNS lymphoma - null regimens
- CNS melanoma
- COVID-19 coronavirus and cancer
- COVID-19 coronavirus medical center experiences
- COVID-19 coronavirus patient experiences
- Cabazitaxel (Jevtana)
- Cabozantinib (Cometriq)
- Calaspargase (Asparlas)
- Calcium phosphate rinse (Caphosol)
- Camrelizumab (AiRuiKa)
- Cancer-related fatigue
- Cangrelor (Kengreal)
- Capecitabine (Xeloda)
- Capivasertib (Truqap)
- Caplacizumab (Cablivi)
- Capmatinib (Tabrecta)
- Carbasalate calcium (Ascal)
- Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer
- Carboplatin (Paraplatin)
- Carcinoma of unknown primary
- Carfilzomib (Kyprolis)
- Carmofur (HCFU)
- Carmustine (BCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel wafer)
- Caspofungin (Cancidas)
- Castleman disease
- Castleman disease - null regimens
- Catumaxomab (Removab)
- Cediranib (Recentin)
- Cefixime (Suprax)
- Celecoxib (Celebrex)
- Cellular therapy conditioning regimens
- Cemiplimab (Libtayo)
- Cephalexin (Keflex)
- Ceritinib (Zykadia)
- Cervical cancer
- Cervical cancer - historical
- Cervical cancer - null regimens
- Cetirizine (Zyrtec)
- Cetuximab (Erbitux)
- Chemotherapy-induced peripheral neuropathy
- Chidamide (Epidaza)
- Chlorambucil (Leukeran)
- Chlorozotocin (DCNU)
- Chlorpheniramine (Chlor-Trimeton)
- Cholangiocarcinoma
- Cholangiocarcinoma - historical
- Cholangiocarcinoma - null regimens
- Chronic lymphocytic leukemia
- Chronic lymphocytic leukemia - historical
- Chronic lymphocytic leukemia - null regimens
- Chronic myeloid leukemia
- Chronic myeloid leukemia, pediatric
- Chronic myeloid leukemia - historical
- Chronic myelomonocytic leukemia
- Cilostazol (Pletal)
- Ciltacabtagene autoleucel (Carvykti)
- Cimetidine (Tagamet)
- Ciprofloxacin (Cipro)
- Cisplatin (Platinol)
- Cixutumumab (IMC-A12)
- Cladribine (Leustatin)
- Clarithromycin (Biaxin)
- Classical Hodgkin lymphoma
- Classical Hodgkin lymphoma, pediatric
- Classical Hodgkin lymphoma, pediatric - historical
- Classical Hodgkin lymphoma - historical
- Classical Hodgkin lymphoma - null regimens
- Clear cell renal cell carcinoma
- Clear cell renal cell carcinoma - null regimens
- Clemastine (Tavist)
- Clinical trials
- Clobetasol
- Clodronate (Bonefos)
- Clofarabine (Clolar)
- Clonazepam (Klonopin)
- Clopidogrel (Plavix)
- Cobimetinib (Cotellic)
- Colchicine (Colcrys)
- Cold agglutinin disease
- Colon cancer
- Colon cancer, RAS wild-type
- Colon cancer - historical
- Colon cancer - null regimens
- Colorectal cancer
- Colorectal cancer, BRAF-mutated
- Colorectal cancer, HER2-positive
- Colorectal cancer, KRAS-mutated
- Colorectal cancer, MSI-H or dMMR
- Colorectal cancer, RAS wild-type
- Colorectal cancer - historical
- Colorectal cancer - null regimens
- Coltuximab ravtansine (SAR-3419)
- Complex multipart regimens
- Compression stockings and sleeves
- Concizumab (Alhemo)
- Conflict of interest
- Congenital thrombotic thrombocytopenic purpura
- Consult topics in hematology and oncology
- Contexts
- Copanlisib (Aliqopa)
- Cortisone
- Craniopharyngioma
- Crenolanib (CP-868,596)
- Crizanlizumab (Adakveo)
- Crizotinib (Xalkori)
- Custirsen (OGX-011)
- Cutaneous T-cell lymphoma
- Cutaneous T-cell lymphoma - null regimens
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Cutaneous squamous cell carcinoma - null regimens
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine
- Cyproterone acetate (Androcur)
- Cytarabine (Ara-C)
- Cytarabine and daunorubicin liposomal (Vyxeos)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus Immune Globulin (Cytogam)
- D5NS
- Dabigatran (Pradaxa)
- Dabrafenib (Tafinlar)